SCN11A
Sodium channel protein type 11 subunit alpha
As of the edition of 20 October 2026, SCN11A (sodium channel protein type 11 subunit alpha, UniProt Q9UI33) has 55 drugs tested at it and 12 companies on the list, 1 on route A and 5 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q9UI33
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Disease areas
- Nervous system; Mental health; Injuries; Cancer; Bones, joints and muscles; Heart and blood vessels; Nutrition and metabolism; Urinary and reproductive
- Registered trials of its drugs
- 2,667
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 44 |
| Active | 3 |
| Went quiet | 7 |
| Withdrawn from market | 1 |
| Total | 55 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Lidocaine | Marketed | Phase 4 | none listed |
| Ropivacaine | Marketed | Phase 4 | none listed |
| Topiramate | Marketed | Phase 4 | none listed |
| Lamotrigine | Marketed | Phase 4 | none listed |
| Carbamazepine | Marketed | Phase 4 | none listed |
| Lacosamide | Marketed | Phase 4 | Ended 2026 |
| Riluzole | Marketed | Phase 4 | none listed |
| Tetracaine | Marketed | Phase 4 | none listed |
| Eslicarbazepine acetate | Marketed | Phase 4 | Ended 2026 |
| Zonisamide | Marketed | Phase 4 | none listed |
| Phenytoin | Marketed | Phase 4 | none listed |
| Articaine | Marketed | Phase 4 | none listed |
12 of 55 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Route B | 5 |
| Engaged | 6 |
| Total on the list | 12 |
| Company | Route |
|---|---|
| Novartis | Route B |
| GSK | Route B |
| Azurity Pharmaceuticals | Route B |
The other 9 companies at SCN11A
In the product12 companies in all; 9 are not named here, and no score is.
See the 12 companies at SCN11A, ranked, with the facts behind eachRequest access. Nothing is shown until you do.